Should Canadian patients look forward to aducanumab for Alzheimer disease?

CMAJ. 2021 Sep 13;193(36):E1430-E1431. doi: 10.1503/cmaj.211134.
No abstract available

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / prevention & control
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Kanada
  • Dose-Response Relationship, Drug
  • Humans
  • Molecular Targeted Therapy / standards*
  • Primary Health Care / organization & administration*

Substances

  • Antibodies, Monoclonal, Humanized
  • aducanumab